ArticlePloS one2026
Burden of acute lymphoblastic leukemia in children and adolescents in low- and middle-income countries from 1990 to 2023 and projections to 2050: A systematic analysis from the global burden of disease study 2023.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute Lymphoblastic Leukemia (ALL) is the most common and curable malignancy in children and adolescents, yet it remains a significant health threat. Despite global survival improvements driven by new drugs and treatment protocols, comprehensive data on disease burdens and attributable risk factors across diverse socio-economic contexts remain limited. This study evaluated the epidemiological characteristics, temporal trends, and modeled attributable risk factors of ALL in LMICs from 1990 to 2023.
methodsUsing GBD 2023 data, we analyzed ALL incidence, mortality, and DALYs in children and adolescents (0-19 years), stratified by World Bank income groups. We assessed temporal trends via Joinpoint regression, projected burdens to 2050 using the Bayesian Age-Period-Cohort (BAPC) model, and evaluated risk attribution for occupational benzene and formaldehyde exposure.
resultsIn 2023, LMICs reported 64,477 new ALL cases and 30,909 deaths, with a higher burden in males. While the age-standardized incidence rate (ASIR) declined overall, absolute cases rose due to population growth. Although occupational benzene and formaldehyde exposure were the only modeled risk factors, their Population Attributable Fractions (PAFs) were negligible (<1%), indicating minimal contribution to the total burden. Projections suggest the age-standardized ALL burden will continue declining through 2050, with the sharpest decrease expected in low-income countries.
conclusionGlobally, childhood and adolescent ALL mortality and DALYs are declining, yet the burden remains substantial in many LMICs, with the smallest improvements observed in low-income countries from 1990 to 2023. Occupational benzene and formaldehyde exposure contributed minimally to the total burden (PAFs < 1%), indicating that direct occupational exposure is rare in children. These findings suggest that the persistent burden in LMICs is primarily driven by healthcare system factors rather than occupational environmental exposures. Therefore, efforts to further reduce ALL mortality and DALYs in high-burden regions should address gaps in healthcare access and treatment delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.